Skip to main content

Volume 17 Supplement 1

Testing for chronic hepatitis B and C – a global perspective

Research

Publication of this supplement was funded by the WHO. Information about the source of funding for specific projects can be found in the individual articles. The articles have undergone the journal's standard peer review process for supplements. PE is a WHO staff member and has no financial conflicts of interest. RC has received funding from the U.S. Agency for Healthcare Research and Quality to conduct systematic reviews on hepatitis C screening. MH receives funding from the NHMRC in Australia for a Principal Research Fellowship. The Burnet Institute receives funding from Gilead Science, Abbvie and BMS for investigator initiated research, for which MH is the lead investigator, and receives support from the Victorian Government through the Victorian Operational Infrastructure Support Program. PH is an employee of BioMed Central. The Supplement Editors declare that they were not involved in the peer review process for any paper on which they are an author.

Edited by Philippa Easterbrook, Roger Chou, Margaret Hellard and Philippa Harris

New Content Item​​​​​​​


  1. Linking persons with hepatitis B (HBV) and hepatitis C (HCV) infection with appropriate prevention and treatment requires that they first be diagnosed. The World Health Organization (WHO) has developed its fir...

    Authors: Roger Chou, Philippa Easterbrook and Margaret Hellard

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):694

    Content type: Method

    Published on:

  2. Chronic Hepatitis B Virus (HBV) infection is characterised by the persistence of hepatitis B surface antigen (HBsAg). Expanding HBV diagnosis and treatment programmes into low resource settings will require hi...

    Authors: Ali Amini, Olivia Varsaneux, Helen Kelly, Weiming Tang, Wen Chen, Debrah I. Boeras, Jane Falconer, Joseph D. Tucker, Roger Chou, Azumi Ishizaki, Philippa Easterbrook and Rosanna W. Peeling

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):698

    Content type: Research

    Published on:

  3. Although direct-acting antivirals can achieve sustained virological response rates greater than 90% in Hepatitis C Virus (HCV) infected persons, at present the majority of HCV-infected individuals remain undia...

    Authors: Weiming Tang, Wen Chen, Ali Amini, Debi Boeras, Jane Falconer, Helen Kelly, Rosanna Peeling, Olivia Varsaneux, Joseph D. Tucker and Philippa Easterbrook

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):695

    Content type: Research

    Published on:

  4. Initial serological testing for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is conducted using either rapid diagnostic tests (RDT) or laboratory-based enzyme immunoassays (EIA)s for d...

    Authors: John V. Parry, Philippa Easterbrook and Anita R. Sands

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):705

    Content type: Research

    Published on:

  5. The detection and quantification of hepatitis B (HBV) DNA and hepatitis C (HCV) RNA in whole blood collected on dried blood spots (DBS) may facilitate access to diagnosis and treatment of HBV and HCV infection...

    Authors: Berit Lange, Teri Roberts, Jennifer Cohn, Jamie Greenman, Johannes Camp, Azumi Ishizaki, Luke Messac, Edouard Tuaillon, Philippe van de Perre, Christine Pichler, Claudia M. Denkinger and Philippa Easterbrook

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):693

    Content type: Research

    Published on:

  6. Dried blood spots (DBS) are a convenient tool to enable diagnostic testing for viral diseases due to transport, handling and logistical advantages over conventional venous blood sampling. A better understandin...

    Authors: Berit Lange, Jennifer Cohn, Teri Roberts, Johannes Camp, Jeanne Chauffour, Nina Gummadi, Azumi Ishizaki, Anupriya Nagarathnam, Edouard Tuaillon, Philippe van de Perre, Christine Pichler, Philippa Easterbrook and Claudia M. Denkinger

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):700

    Content type: Research

    Published on:

  7. Many people living with chronic HBV infection remain undiagnosed until later stages of disease. Increasing testing and treatment rates form part of the strategy to respond to the WHO goal of eliminating viral ...

    Authors: Shevanthi Nayagam, Elisa Sicuri, Maud Lemoine, Philippa Easterbrook, Lesong Conteh, Timothy B. Hallett and Mark Thursz

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):692

    Content type: Review

    Published on:

  8. Hepatitis C virus (HCV) infection represents a major public health burden with diverse epidemics worldwide, but at present, only a minority of infected persons have been tested and are aware of their diagnosis...

    Authors: Jake R. Morgan, Maria Servidone, Philippa Easterbrook and Benjamin P. Linas

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):697

    Content type: Review

    Published on:

  9. There have been few reports on programmatic experience of viral hepatitis testing and treatment in resource-limited settings. To inform the development of the 2017 World Health Organization (WHO) viral hepatit...

    Authors: Azumi Ishizaki, Julie Bouscaillou, Niklas Luhmann, Stephanie Liu, Raissa Chua, Nick Walsh, Sarah Hess, Elena Ivanova, Teri Roberts and Philippa Easterbrook

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):696

    Content type: Research

    Published on:

  10. Approximately 8% of HIV-infected individuals are co-infected with hepatitis B virus (HBV) in sub-Saharan Africa (SSA). Knowledge of HBV status is important to guide optimal selection of antiretroviral therapy ...

    Authors: Patrick A. Coffie, Matthias Egger, Michael J. Vinikoor, Marcel Zannou, Lameck Diero, Akouda Patassi, Mark H. Kuniholm, Moussa Seydi, Guillaume Bado, Ponsiano Ocama, Monique I. Andersson, Eugène Messou, Albert Minga, Philippa Easterbrook, Kathryn Anastos, François Dabis…

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):706

    Content type: Review

    Published on:

  11. Access to hepatitis B virus (HBV) and hepatitis C virus (HCV) diagnostics remains a key bottleneck in scale-up of access to HBV and HCV treatment, particularly in low- and middle-income countries (LMICs) that ...

    Authors: Elena Ivanova Reipold, Alessandra Trianni, Douglas Krakower, Stefano Ongarello, Teri Roberts, Philippa Easterbrook and Claudia Denkinger

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):702

    Content type: Research

    Published on:

  12. The current low access to virological testing to confirm chronic viraemic HCV infection in low- and middle-income countries (LMIC) is limiting the rollout of hepatitis C (HCV) care. Existing tests are complex,...

    Authors: Elena Ivanova Reipold, Philippa Easterbrook, Alessandra Trianni, Nivedha Panneer, Douglas Krakower, Stefano Ongarello, Teri Roberts, Veronica Miller and Claudia Denkinger

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):707

    Content type: Research

    Published on:

  13. Innovation contests are a novel approach to elicit good ideas and innovative practices in various areas of public health. There remains limited published literature on approaches to deliver hepatitis testing. ...

    Authors: Joseph D. Tucker, Kathrine Meyers, John Best, Karyn Kaplan, Razia Pendse, Kevin A. Fenton, Isabelle Andrieux-Meyer, Carmen Figueroa, Pedro Goicochea, Charles Gore, Azumi Ishizaki, Giten Khwairakpam, Veronica Miller, Antons Mozalevskis, Michael Ninburg, Ponsiano Ocama…

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):701

    Content type: Research

    Published on:

  14. A large burden of undiagnosed hepatitis virus cases remains globally. Despite the 257 million people living with chronic hepatitis B virus infection, and 71 million with chronic viraemic HCV infection, most pe...

    Authors: Rosanna W. Peeling, Debrah I. Boeras, Francesco Marinucci and Philippa Easterbrook

    Citation: BMC Infectious Diseases 2017 17(Suppl 1):699

    Content type: Review

    Published on: